- Details
- Karim Fizazi joins Alicia Morgans in discussing the ARASENS trial which examined darolutamide in combination with docetaxel and androgen deprivation therapy (ADT) compared to docetaxel and ADT. The ARASENS trial is an international, double-blind, phase 3 study that enrolled patients with mHSPC and ECOG performance status 0 or 1. Drs. Morgans and Fizazi detail the overall survival data presented at...
|
- Details
- Thomas Keane is joined by Heather Payne to discuss the management of metastatic hormone-sensitive prostate cancer. While treatment with androgen deprivation therapy (ADT) provides initial responses, progression is common and a large proportion of prostate cancer-related deaths occur among men initially diagnosed with metastatic disease. Dr. Payne focuses her discussion on multiple trials determini...
|
- Details
- Alicia Morgans and Karim Fizazi discuss the recent analysis of the PEACE-1 study. The PEACE-1 study is a phase 3 trial evaluating abiraterone plus standard of care in M1 disease and local radiation therapy directed to the prostate primary. Dr. Fizazi discusses the study design and the first results he presented at ASCO 2021, specifically treatment with androgen deprivation therapy (ADT), docetaxel...
|
- Details
- Alicia Morgans with Arun Azad and Declan Murphy about an ongoing clinical trial exploring the use of Lutetium PSMA for treating newly diagnosed metastatic hormone-sensitive prostate cancer. Dr. Azad reveals that the trial aims to assess whether adding Lutetium PSMA to standard chemo-hormonal therapy improves efficacy. The study has garnered significant interest, enrolling over a quarter of its tar...
|
- Details
- In an abstract review session at the 2021 ASCO annual meeting, Lisa Horvath, PhD, MBBS, FRACP, reviewed 3 abstracts: PEACE-1, the SWOG S1216 trial, and the PEACE-III trial. She expanded her conversation about these three abstracts in a discussion with Alicia Morgans, MD, MPH. In the primary conversation about the PEACE-1 trial, Dr. Horvath discussed the main interest, in this phase III trial, to b...
|
- Details
- The SWOG S1216 is a Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer (mHSPC). Tak is an oral selective nonsteroidal 17, 20-lyase inhibitor that blocks the synthesis of gonadal and adrenal androgens and in this trial the clinical benefit of Tak wi...
|
- Details
- In a conversation with Alicia Morgans on clinical characteristics of patients with metastatic hormone-sensitive prostate cancer (mHSPC) and identifying subsets of patients to improve personalized treatments, Christopher Sweeney shares data from a European Urology publication Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androge...
|
- Details
- In a presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Karim Fizazi presented the first results of the PEACE-1 trial. PEACE-1 is a phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer. Adding abiraterone to ADT + docetaxel significantly impro...
|
- Details
- In this conversation with Alicia Morgans, MD, MPH, Drs Scott Tagawa and Stephen Freedland highlight real-world evidence of survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) in the Veterans Health Administration system. Drs. Tagawa, Freedland, and colleagues used the Veterans Health Administration claims data to identify patients with mCSPC who initiated ADT...
|
- Details
- Matthew Deek and Phuoc Tran join Charles Ryan to discuss their recent paper "The Mutational Landscape of Metastatic Castration-Sensitive Prostate Cancer: The Spectrum Theory Revisited" published in European Urology. The aim of this study was to characterize the somatic mutational landscape across the disease spectrum of metastatic castration-sensitive prostate cancer (mCSPC) to elucidate a biologi...
|
